Identification of 2 hypothetical genes involved in Neisseria meningitidis cathelicidin resistance

Journal of Infectious Diseases

Volumn 197, Issue 8, 2008, Pages 1124-1132

  Frigimelica, Elisabetta ^a   Bartolini, Erika ^a   Galli, Giuliano ^a   Grandi, Guido ^a,b   Grifantini, Renata ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; CATHELIN RELATED ANTIMICROBIAL PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE INTERACTION; GENETIC RESISTANCE; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTEREMIA; BLOTTING, WESTERN; DRUG RESISTANCE, MICROBIAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MENINGITIS, MENINGOCOCCAL; MICE; MICE, INBRED BALB C; MUTAGENESIS, INSERTIONAL; NEISSERIA MENINGITIDIS, SEROGROUP B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; UP-REGULATION;

EID: 42549116264     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/533456     Document Type: Article

References (35)

1. Peschel A. How do bacteria resist human antimicrobial peptides? Trends Microbiol 2002; 10:179-86.
2. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1:156-64.
3. Devine DA, Hancock RE. Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Des 2002; 8:703-14.
4. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006; 18:24-30.
5. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414:454-7.
6. Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000; 1:141-50.
7. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 2001; 69:691-7.
8. Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 2002; 80:549-61.
9. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999; 341:501-13.
10. Oren Z, Shai Y. Mode of action of linear amphipatic alpha-helical antimicrobial peptides. Biopolymers 1998; 47:451-63.
11. Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins CL. Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci USA 1991; 88:3952-6.
12. Schonwetter BS, Stolzenberg ED, Zasloff MA. Epithelial antibiotics induced at sites of inflammation. Science 1995; 267:1645-8.
13. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/probactenecin- like protein of human neutrophil specific granules. FEBS Lett 1995; 368:173-6.
14. Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96:3086-93.
15. Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001; 117:91-7.
16. Taha MK, Deghmane AE, Antignac A, Zarantonelli ML, Larribe M, Alonso JM. The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol 2002; 10:376-82.
17. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415:389-95.
18. Grifantini R, Bartolini E, Muzzi A, et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002; 20:914-21.
19. Trieu-Cuot P, Poyart-Salmeron C, Carlier C, Courvalin P. Nucleotide sequence of the erythromycin resistance gene of the conjugative transposon Tn1545. Nucleic Acids Res 1990; 18:3660.
20. Grifantini R, Frigimelica E, Delany I, Bartolini E, Giovinazzi S, Balloni S. Characterization of a novel Neisseria meningitidis Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Mol Microbiol 2004; 54:962-79.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
22. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005; 77:451-9.
23. Bergman P, Johansson L, Wan H, et al. Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun 2006; 74:6982-91.
24. Hofmann K, Stoffel W. TMbase - a database of membrane spanning proteins segments. Biol Chem Hoppe Seyler 1993; 374:166.
25. Wilks KE, Dunn KL, Farrant JL, et al. Periplasmic superoxide dismutase in meningococcal pathogenicity. Infect Immun 1998; 66:213-7.
26. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287:1809-15.
27. Chen CJ, Tobiason DM, Thomas CE, Shafer WM, Seifert HS, Sparling PF. A mutant form of the Neisseria gonorrhoeae pilus secretin protein PilQ allows increased entry of heme and antimicrobial compounds. J Bacteriol 2004; 186:730-9.
28. Tzeng YL, Ambrose KD, Zughaier S, et al. Cationic antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol 2005; 187:5387-96.
29. Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkonen A, Jonsson AB. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 2005; 23:2214-7.
30. Gudmundsson GH, Agerberth B. Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods 1999; 232:45-54.
31. Rosenberger CM, Gallo RL, Finlay BB. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc Natl Acad Sci USA 2004; 101:2422-7.
32. Brodsky IE, Ghori N, Falkow S, Monack D. Mig-14 is an inner membrane-associated protein that promotes Salmonella typhimurium resistance to CRAMP, survival within activated macrophages and persistent infection. Mol Microbiol 2005; 55:954-72.
33. Peschel A, Jack RW, Otto M, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001; 193:1067-76.
34. Ochsner UA, Vasil AI, Johnson Z, Vasil ML. Pseudomonas aeruginosa fur overlaps with a gene encoding a novel outer membrane lipoprotein, OmlA. J Bacteriol 1999; 181:1099-109.
35. Ramos JL, Martinez-Bueno M, Molina-Henares AJ, et al R. The TetR family of transcriptional repressors. Microbiol Mol Biol Rev 2005; 69:326-56.